Research & Education

Liquid Biopsies for the Identification of EGFR Mutations and for the Prediction of Lung Cancer Recurrence

DENVER – Three manuscripts published in the recent issue of the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), explored the versatility of liquid biopsies by identifying EGFR mutations using circulating tumor DNA (ctDNA) in urine and plasma and examining circulating tumor cells (CTCs) in plasma to predict the risk of lung cancer recurrence after surgical resection. Collectively, these findings illustrate the potential and reach of liquid biopsies in both identifying patients suitable for targeted treatment as well as predicting cancer recurrence.

Nivolumab Cost-Effectiveness Improves by Selecting Non-Squamous NSCLC PD-L1+ Patients to Receive Treatment

DENVER – Nivolumab (NIV), a checkpoint inhibitor approved for all squamous and non-squamous non-small cell lung cancer (NSCLC) patients in 2015, is not cost-effective when compared to treatment with docetaxel (DOC), chemotherapy medication. However, a Swiss analysis showed the cost-effectiveness of NIV is improved when patients are treated with NIV based on PD-L1 positivity (PD-L1+), or if there is a reduction in dose or drug price.

CAP/IASLC/AMP Molecular Testing Guideline: Open Comment Period

Public Open Comment Period from June 28 to Aug. 2, 2016

Thank you for your interest in the public open comment period. The current draft recommendations are the product of an Expert Panel charged with reaffirming, updating, and revising the Molecular Testing Guideline for Selection of Lung Cancer Patients for Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) published in 2013.

Adjuvant Chemotherapy Improves Overall Survival in Patients with Stage IB Non-Small Cell Lung Cancer

DENVER – The use of adjuvant chemotherapy in early-stage non-small cell lung cancer (NSCLC) patients improves overall survival (OS) and 5-year OS in patients with tumor sizes ranging from 3.1 – 7 cm.

APLCC 2016 Calls on Asian-Pacific Governments to Help Reduce Lung Cancer Deaths by 1/3rd by 2030

APLCC 2016
 

IASLC Consensus Statement on Optimizing Management of EGFR Mutation Positive NSCLC Patients

DENVER – The International Association for the Study of Lung Cancer (IASLC) created the 2016 consensus statement on optimizing management of epidermal growth factor receptor (EGFR) mutation positive (M+) non-small cell lung cancer (NSCLC) patients, published in the Journal of Thoracic Oncology (JTO), to discuss key pathologic, diagnostic, and therapeutic considerations. The statement also makes recommendations for clinical guidance and research priorities, such as optimal choice of EGFR tyrosine kinase inhibitors (TKIs), management of brain metastasis, role of re-biopsies, and use of circulating free DNA (cfDNA) for molecular studies.

Pages